NCT03267186 2023-08-01
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
Stanford University
Phase 2 Completed
Clinical Trials
3 trialsNCT03642236 2018-08-22
Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT02635074 2018-05-14
Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Phase 1 Terminated